# Prevention of Epstein-Barr Virus Reactivation With the ATG-based Haploidentical Protocol Combined With Rituximab in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

> **NCT07693881** · NA · RECRUITING · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 106 (estimated)

## Conditions studied

- EBV Infection After Allogenic HSCT

## Interventions

- **DRUG:** Rituximab (R)

## Key facts

- **NCT ID:** NCT07693881
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2028-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 106 (ESTIMATED)
- **Last updated:** 2026-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07693881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07693881, "Prevention of Epstein-Barr Virus Reactivation With the ATG-based Haploidentical Protocol Combined With Rituximab in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07693881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*